EMEA-001207-PIP03-20 - paediatric investigation plan
Obinutuzumab
PIPHuman
Roche Registration GmbH
E-mail: global.paediatrics@roche.com
Tel. +41 616879411
P/0512/2020 : EMA decision of 22 December 2020 on the refusal of a product specific waiver for obinutuzumab (Gazyvaro) (EMEA-001207-PIP03-20)